Search This Blog

1

Labels

Cancer (150) Breast (38) Study (38) Health (32) Patients (31) Treatment (27) Could (23) Therapy (19) Research (17) Against (12) Blood (11) Disease (11) linked (11) Diabetes (10) Early (10) Prevent (10) Survival (10) Treatments (7) higher (7) surgery (7) Might (6) Prostate (6) Tumors (6) During (5) Effects (5) Growth (5) Chemotherapy (4) Drinking (4) Prevention (4) Obama (3) Obesity (3) Without (3) associated (3) Experts (2) Important (2) Infection (2) About (1) Analysis (1) Causes (1) Eliminate (1) stroke (1)

AD

Showing posts with label crucial. Show all posts
Showing posts with label crucial. Show all posts

Monday, September 23, 2013

Microfluidic platform gives clear look at a crucial step in cancer metastasis

Sep. 20, 2013 — Cancer cells metastasize in several stages -- first by invading surrounding tissue, then by infiltrating and spreading via the circulatory system. Some circulating cells work their way out of the vascular network, eventually forming a secondary tumor.

While the initial process by which cancer cells enter the bloodstream -- called intravasation -- is well characterized, how cells escape blood vessels to permeate other tissues and organs is less clear. This process, called extravasation, is a crucial step in cancer metastasis.

Now researchers at MIT have developed a microfluidic device that mimics the flow of cancer cells through a system of blood vessels. Using high-resolution time-lapse imaging, the researchers captured the moments as a cancer cell squeezes its way through a blood vessel wall into the surrounding extracellular matrix. The process is "highly dynamic," as they write in a paper published in the journal Integrative Biology; a better understanding of it may help scientists identify therapies to prevent metastasis.

"Now that we have a model for extravasation, you can think about using it as a screen for drugs that could prevent it," says Roger Kamm, the Cecil and Ida Green Distinguished Professor of Biology and Mechanical Engineering at MIT. "We could take circulating tumor cells from a patient and subject those cells to a handful of factors or drugs. That's ultimately what we'd like to do, but in the process we're learning a lot as we go along."

Kamm's co-authors on the paper include graduate students Michelle Chen, Jordan Whisler and Jessie Jeon.

Seeding blood vessels

As tumor cells make their way through the circulatory system, some "arrest," or pause at a particular location, adhering to a blood vessel's wall -- the first stage of extravasation. Scientists have thought that this cell arrest occurs in one of two ways: A cell may send out sticky projections that grab onto the vessel lining, or it may be too big to pass through, literally becoming trapped within the vessel.

To investigate which possibility is more likely, the researchers grew a network of tiny blood vessels from a solution of human umbilical-cord endothelial cells. They injected a solution containing vascular cells into a small microfluidic device containing a reservoir of hydrogel, along with growth factors normally present in the developing circulatory system. Within days, an intricate system of microvessels took shape, with each about one millimeter long and 10 to 100 microns in diameter -- dimensions similar to the body's small capillaries.

The group then pumped tumor cells through the vascular network, using a line of breast cancer cells known to be particularly invasive. Using high-resolution confocal microscopy, the team watched as tumor cells flowed through the miniature circulatory system. They observed that the majority of cells that arrested along a vessel did so due to entrapment -- that is, they simply became stuck.

A tumor cell finds a way out

With time-lapse images, the researchers took a closer look at the progression of events following cell arrest. Once a tumor cell becomes trapped, they observed that it sends out long, thin filaments that push against a vessel wall, eventually creating a small hole in the endothelial lining. More and more of the cell squeezes through as the holes give way, and eventually, even the cell's nucleus -- thought to be a relatively rigid, nondeformable structure -- is able to escape.

To their surprise, the researchers found that the nucleus made it through the vessel wall earlier and more quickly than they anticipated, squeezing through in about 15 minutes -- "a tiny chunk of the time it takes for this entire cell to extravasate," Chen notes.

Interestingly, Chen points out, once a tumor cell has completely exited a blood vessel, the endothelium appears to heal itself, closing the gaps that the cell initially created. "That suggests that the endothelial barrier has some kind of active role in repairing itself after this invasion by the tumor cell," Chen says.

In addition to observing the extravasation of single tumor cells, the group also looked at the behavior of cell clusters -- two or more cancer cells that accumulate in a blood vessel. From their observations, the researchers found that almost 70 percent of cell clusters broke through a blood barrier, compared with less than 10 percent of single cells.

But some cells that make it out of the circulatory system may still fail to metastasize. To see whether a cell's ability to extravasate correlates with its metastatic potential, the group compared the efficiency of extravasation of different cancer cell lines. The lines included breast cancer cells, cells from fibrosarcoma (a cancer of the connective tissue), and a line of nonmetastatic cancer cells.

Sure enough, the team observed that the most metastatic cells (fibrosarcoma cells) were also the most likely to extravasate, compared with breast cancer and nonmetastatic cells -- a finding suggesting that targeting drugs to prevent extravasation may slow cancer metastasis.

Going forward, the group is looking into how likely a given cancer cell is to proliferate and aggregate with others once it has exited into the surrounding tissue. The researchers are modeling various tissues within the microfluidic platform, including bone, to study how cancer cells form the beginnings of a secondary tumor.

"Although this platform isn't an in-vivo platform and obviously can't capture all the aspects that happen in vivo, we've come a lot closer to creating an in-vitro platform that's even more physiologically relevant, high-resolution and high-throughput than a lot of previous platforms," Chen says.


View the original article here

Friday, September 20, 2013

Protein 'motif' crucial to telomerase activity

Sep. 19, 2013 — It is difficult to underestimate the importance of telomerase, an enzyme that is the hallmark of both aging and the uncontrolled cell division associated with cancer. In an effort to understand and control telomerase activity, researchers at The Wistar Institute have discovered a protein "motif," named TFLY, which is crucial to the function of telomerase. Altering this motif disrupts telomerase function, they found, a fact that they believe will help them in their efforts to identify inhibitors of telomerase with potential cancer therapeutic properties.

Their findings are published in the October 8 issue of the journal Structure, available online now.

"Telomerase is a unique protein-RNA complex where the protein subunit uses its RNA component as a template to add identical fragments of DNA to the end of chromosomes," said Emmanuel Skordalakes, Ph.D., associate professor in the Gene Expression and Regulation program of Wistar's NCI-designated Cancer Center. "We identified a motif in the protein component of telomerase that controls how the enzyme carries out its activity in vertebrates such as ourselves."

"If you disrupt this segment of the protein, by altering its amino acid sequence, you disrupt the ability of telomerase to function," Skordalakes explained. "Obviously, this information can be used in our efforts to identify drug therapies that kill cancer cells by targeting telomerase activity."

Telomerase is an enzyme that replicates the ends of chromosomes (sections of DNA called telomeres), replacing the DNA lost when chromosomes are copied before cell division and, therefore, maintaining the stability of the genome. It performs this critical service in embryonic development, growing organisms and in a few specialized adult cell lines, including stem cells.

In most normal adult cells, however, telomerase is switched off almost entirely to prevent the dangers of runaway cell proliferation. Without telomerase, adult cells senesce (grow old) after about 50-55 rounds of cell division because the telomeres get too short to provide the buffer required to protect the ends of chromosomes and stabilize the cell's genetic code.

It is now established that nearly 90 percent of cancers develop a way of reactivating telomerase as a means of survival. Inhibiting telomerase function has been viewed as an ideal way to put the brakes on a wide range of cancers. According to Skordalakes, one way to do so would be to disrupt the protein RNA complex that comprises the core of the telomerase enzyme. The RNA binding domain (TRBD) of telomerase is a crucial component to this process and, therefore, the enzyme's ability to work.

In 2007, the Skordalakes laboratory was the first to obtain the three-dimensional structure of TRBD. Since then, his team has been creating molecular inhibitors to target the TRBD RNA-binding pockets as means to inhibit telomerase enzymatic activity.

The present study arose as the Skordalakes laboratory sought to better understand the role of TRBD in telomerase function. They engineered a truncated version of the protein subunit of a vertebrate telomerase, consisting of TRBD and a conserved portion of the N-terminal region of the protein. Within this portion they identified the TFLY, a conserved element that they showed is involved in binding the RNA component of telomerase and this interaction is important for telomerase protein-RNA assembly and activity.

"This TFLY motif comprises a significant part of the binding pocket that enables the enzyme to grapple the RNA template and guide it to the active site of the enzyme for catalysis," Skordalakes said, "but it also facilitates the stable association of the protein with its RNA component thus forming a fully functional telomerase enzyme."


View the original article here

Friday, September 13, 2013

'Crucial' new miscarriage insight

12 September 2013 Last updated at 00:54 GMT By James Gallagher Health and science reporter, BBC News Pregnant woman More than one in seven pregnancies end in miscarriage. Fertility scientists say they have made a "crucial breakthrough" in understanding why some women have repeated miscarriages.

There has been debate about whether giving steroids would help women who have lost multiple pregnancies.

University of Warwick researchers say they have now shown how low steroid levels lead to some miscarriages.

Experts said identifying the right women for treatment would be key, as steroids may make the problem worse.

More than one in seven pregnancies end in miscarriage.

Many women will successfully have a baby at the next attempt, but recurrent miscarriage - losing three or more pregnancies in a row - affects one in 100 in the UK.

Prof Siobhan Quenby from the University of Warwick said: "It causes incredible psychological distress and anguish.

"The routine advice in the UK is if blood tests identify no cause then there's no treatment, that's terribly unacceptable to patients."

Steroids?

The scientific debate centred around a part of the immune system called NK cells, which appear in higher levels in the wombs of some women who miscarry.

There were suggestions steroids could help these women and yet it was not clear how NK cells could cause a miscarriage and they were known to be important for an embryo to implant in the womb.

The idea was not fully tested in large clinical trials.

Continue reading the main story
"I think this is a crucial breakthrough in the understanding of recurrent miscarriage, it's the gateway to the clinical trial.”

End Quote Prof Nick Macklon University of Southampton Now researchers publishing in The Journal of Clinical Endocrinology and Metabolism, believe that the NK cells are merely a marker of something more serious happening in the womb lining.

Tests suggest that low steroid levels make the womb itself less likely to accept an embryo and damage the way it nourishes a foetus that does implant. These processes in turn lead to higher NK cell levels.

Prof Quenby said: "This work is really exciting because after years of controversy and doubt, we have a crucial breakthrough."

Care

She said up to one in three women had high NK levels and is now calling for a clinical trial to test whether steroids would help them.

In the meantime she said women should not be buying steroids in an attempt to treat themselves, as too much could also lead to miscarriage.

"It is really important women do not go out and take steroids, they might be in the category when it will do more harm."

Nick Macklon, a professor of gynaecology and obstetrics at the University of Southampton, said the field was lacking understanding of what was happening in miscarriage.

He told the BBC: "This is a crucial breakthrough in the understanding of recurrent miscarriage, it's the gateway to the clinical trial.

"But what this shows is that steroids shouldn't be given to all, we need to be sure that is the problem in women before they're given."


View the original article here